Oculis (OCS) Competitors $17.73 +1.11 (+6.68%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$17.65 -0.08 (-0.45%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. RARE, CNTA, MOR, IMVT, XENE, VKTX, OGN, KNSA, NAMS, and BHCShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Ultragenyx Pharmaceutical (RARE), Centessa Pharmaceuticals (CNTA), MorphoSys (MOR), Immunovant (IMVT), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), and Bausch Health Cos (BHC). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Its Competitors Ultragenyx Pharmaceutical Centessa Pharmaceuticals MorphoSys Immunovant Xenon Pharmaceuticals Viking Therapeutics Organon & Co. Kiniksa Pharmaceuticals International NewAmsterdam Pharma Bausch Health Cos Ultragenyx Pharmaceutical (NASDAQ:RARE) and Oculis (NASDAQ:OCS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Which has more volatility & risk, RARE or OCS? Ultragenyx Pharmaceutical has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Which has preferable valuation & earnings, RARE or OCS? Oculis has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Oculis is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$560.23M5.07-$569.18M-$5.53-5.33Oculis$780K992.43-$97.43M-$2.67-6.64 Is RARE or OCS more profitable? Ultragenyx Pharmaceutical has a net margin of -87.34% compared to Oculis' net margin of -13,958.12%. Oculis' return on equity of -90.31% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-87.34% -237.48% -37.66% Oculis -13,958.12%-90.31%-67.85% Do analysts recommend RARE or OCS? Ultragenyx Pharmaceutical presently has a consensus target price of $81.50, suggesting a potential upside of 176.55%. Oculis has a consensus target price of $35.75, suggesting a potential upside of 101.64%. Given Ultragenyx Pharmaceutical's higher probable upside, equities analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Oculis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to RARE or OCS? In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Oculis. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 5 mentions for Oculis. Ultragenyx Pharmaceutical's average media sentiment score of 1.08 beat Oculis' score of 0.30 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in RARE or OCS? 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryUltragenyx Pharmaceutical beats Oculis on 10 of the 16 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$725.67M$3.16B$5.79B$10.46BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-6.6421.03348.8626.86Price / Sales992.43447.99555.40125.65Price / CashN/A44.8326.0131.15Price / Book9.289.8315.996.50Net Income-$97.43M-$52.82M$3.29B$271.25M7 Day Performance0.40%3.07%200.40%3.27%1 Month Performance-0.67%5.37%184.31%8.15%1 Year Performance48.37%16.89%331.44%26.52% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis2.8905 of 5 stars$17.73+6.7%$35.75+101.6%+47.8%$725.67M$780K-6.642Analyst DowngradeGap UpHigh Trading VolumeRAREUltragenyx Pharmaceutical4.3965 of 5 stars$29.00-4.3%$81.50+181.0%-49.8%$2.92B$560.23M-5.241,294CNTACentessa Pharmaceuticals3.185 of 5 stars$22.02+1.0%$32.44+47.3%+41.0%$2.92B$6.85M-12.30200MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730IMVTImmunovant2.2494 of 5 stars$15.53-3.9%$33.60+116.4%-46.7%$2.82BN/A-5.45120XENEXenon Pharmaceuticals2.503 of 5 stars$35.99-0.6%$53.30+48.1%-6.8%$2.79B$7.50M-10.14210Positive NewsVKTXViking Therapeutics4.4238 of 5 stars$24.08-2.9%$87.50+263.4%-62.8%$2.79BN/A-15.7420Analyst ForecastOGNOrganon & Co.4.5697 of 5 stars$10.39-2.5%$17.33+66.9%-45.7%$2.77B$6.40B3.864,000Positive NewsKNSAKiniksa Pharmaceuticals International2.5377 of 5 stars$36.56-1.5%$41.17+12.6%+40.7%$2.75B$423.24M914.23220Positive NewsNAMSNewAmsterdam Pharma3.1458 of 5 stars$24.12-0.3%$41.55+72.2%+69.9%$2.72B$45.56M-14.894Positive NewsBHCBausch Health Cos4.6074 of 5 stars$7.17-1.2%$9.00+25.5%-15.0%$2.69B$9.86B27.5820,700Analyst Upgrade Related Companies and Tools Related Companies RARE Competitors CNTA Competitors MOR Competitors IMVT Competitors XENE Competitors VKTX Competitors OGN Competitors KNSA Competitors NAMS Competitors BHC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCS Stock Alerts